The estimated Net Worth of Lota S. Zoth is at least $202 millier dollars as of 15 May 2024. Ms. Zoth owns over 2,166 units of Inovio Pharmaceuticals Inc stock worth over $42,961 and over the last 9 years she sold INO stock worth over $3,192. In addition, she makes $155,766 as Independent Director at Inovio Pharmaceuticals Inc.
Sign up
Ms. Zoth INO stock SEC Form 4 insiders trading
Lota has made over 9 trades of the Inovio Pharmaceuticals Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently she exercised 2,166 units of INO stock worth $14,187 on 15 May 2024.
The largest trade she's ever made was exercising 19,000 units of Inovio Pharmaceuticals Inc stock on 15 May 2023 worth over $124,450. On average, Lota trades about 2,382 units every 51 days since 2016. As of 15 May 2024 she still owns at least 6,559 units of Inovio Pharmaceuticals Inc stock.
You can see the complete history of Ms. Zoth stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Lota Zoth biography
Lota S. Zoth CPA serves as Independent Director of the Company. Ms. Zoth qualifies to serve on our Board as a result of her years of experience in senior financial roles in a variety of commercial-stage companies over a 35-year career. She currently serves as the chairman of the board of directors of the publicly held biopharmaceutical company Zymeworks, Inc. and also serves on the board of directors of the publicly held biopharmaceutical company Lumos Pharma, Inc. (formerly NewLink Genetics Corporation). Within the last five years, she also served on the boards of directors of the public companies Spark Therapeutics, Inc. and Orexigen Therapeutics, Inc. (which was granted relief under Chapter 11 of the U.S. Bankruptcy Code in 2019). Prior to her board service, she served in senior financial roles in a variety of commercial-stage companies, including serving as MedImmune Inc.’s corporate controller from 2002 to 2004 and its chief financial officer from 2004 until its acquisition by AstraZeneca in 2007. Prior to joining MedImmune in 2002, Ms. Zoth served in financial executive roles at PSINet Inc., Sodexho Marriott Services, Inc., Marriott International and PepsiCo, Inc. Ms. Zoth also served as an auditor at Ernst & Young, LLP and is a Certified Public Accountant. Ms. Zoth holds a B.B.A. in accounting from Texas Tech University.
What is the salary of Lota Zoth?
As the Independent Director of Inovio Pharmaceuticals Inc, the total compensation of Lota Zoth at Inovio Pharmaceuticals Inc is $155,766. There are 9 executives at Inovio Pharmaceuticals Inc getting paid more, with Jong Kim having the highest compensation of $2,588,530.
How old is Lota Zoth?
Lota Zoth is 60, she's been the Independent Director of Inovio Pharmaceuticals Inc since 2019. There are 5 older and 9 younger executives at Inovio Pharmaceuticals Inc. The oldest executive at Inovio Pharmaceuticals Inc is Simon Benito, 75, who is the Independent Chairman of the Board.
What's Lota Zoth's mailing address?
Lota's mailing address filed with the SEC is 660 W. GERMANTOWN PIKE, SUITE 110, PLYMOUTH MEETING, PA, 19462.
Insiders trading at Inovio Pharmaceuticals Inc
Over the last 20 years, insiders at Inovio Pharmaceuticals Inc have traded over $23,656,819 worth of Inovio Pharmaceuticals Inc stock and bought 1,958,377 units worth $5,174,071 . The most active insiders traders include Austin W & Greenhouse David..., Jong Joseph Kim et Felix Theeuwes. On average, Inovio Pharmaceuticals Inc executives and independent directors trade stock every 22 days with the average trade being worth of $745,390. The most recent stock trade was executed by Michael John Sumner on 30 June 2024, trading 2,917 units of INO stock currently worth $19,106.
What does Inovio Pharmaceuticals Inc do?
inovio is revolutionizing the fight against cancer and infectious diseases. our immunotherapies uniquely activate best-in-class immune responses to prevent and treat disease, and have shown clinically significant efficacy with a favorable safety profile. with an expanding portfolio of immune therapies, the company is advancing a growing preclinical and clinical stage product pipeline. partners and collaborators include roche, medimmune, university of pennsylvania, darpa, drexel university, nih, hiv vaccines trial network, national cancer institute, u.s. military hiv research program, and university of manitoba. for more information, visit www.inovio.com.
What does Inovio Pharmaceuticals Inc's logo look like?
Complete history of Ms. Zoth stock trades at Inovio Pharmaceuticals Inc, Zymeworks BC Inc et 89bio Inc
Inovio Pharmaceuticals Inc executives and stock owners
Inovio Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Jong Kim,
President, Chief Executive Officer, Director -
Dr. J. Joseph Kim,
CEO, Pres & Director -
Jacqueline Elizabeth Shea,
Chief Operating Officer -
Peter Kies,
Chief Financial Officer -
Laurent Humeau,
Chief Scientific Officer -
Peter D. Kies,
Chief Financial Officer -
Dr. Laurent M. Humeau,
Chief Scientific Officer -
Dr. Jacqueline E. Shea Ph.D.,
Chief Operating Officer -
David Weiner,
Director -
Lota Zoth,
Independent Director -
Simon Benito,
Independent Chairman of the Board -
Ann Miller,
Independent Director -
Wendy Yarno,
Independent Director -
Jay Shepard,
Independent Director -
Asli Gevgilili,
Chief HR Officer -
Robert L. Crotty J.D.,
Gen. Counsel -
Robert J. Juba Jr.,
Sr. VP of Biological Manufacturing & Clinical Supply Management -
Dr. Jeffrey Skolnik,
Sr. VP of Clinical Devel. -
Dr. Ami Shah Brown,
Sr. VP of Regulatory Affairs -
Jessica C. Lee MS, MPH,
Sr. VP of Clinical Operations & Global Integration -
E. J. Brandreth,
Sr. VP of Quality Assurance -
Ben Matone,
Director of Investor Relations -
Morton Collins,
Director -
George Bickerstaff,
Director -
Adel Mahmoud,
Director -
Mark Bagarazzi,
Chief Medical Officer -
Niranjan Sardesai,
Sr. VP Research & Development -
Nancy Wysenski,
Director -
Avtar S Dhillon,
President & CEO -
Angel Cabrera,
Director -
Austin W & Greenhouse David...,
10% owner -
Dietmar P Rabussay,
V.P. Research & Development -
George F. Iii Mc Hugh,
Vice President, Operations -
Eugene A Larson,
Director -
Felix Theeuwes,
Director -
Robert S Goodenew,
V.P. Corporate Development -
Michael Fons,
VP, Corporate Development -
Kevin Rassas,
Sr. VP Business Development -
Cheryl Jo White,
Chief Medical Officer -
Tee Khiang Ng,
Director -
Robert William Rieder,
Director -
James L Heppell,
Director -
David J Williams,
Director -
Punit Dhillon,
VP, Finance & Operations -
Riaz Amirali Bandali,
Director -
Stephen Rietiker,
Director -
Beng Lee Gan,
Director -
Tazdin Esmail,
Director -
Keith H Wells,
Director -
Chin Cheong Chong,
Director -
Roger D Dansey,
Director -
Michael John Sumner,
Chief Medical Officer